{
    "clinical_study": {
        "@rank": "143077", 
        "acronym": "OLAAC", 
        "arm_group": {
            "arm_group_label": "LAA closure device", 
            "arm_group_type": "Experimental", 
            "description": "Implantation of LAA closure device"
        }, 
        "brief_summary": {
            "textblock": "This is a prospective, non-randomized, study of the safety and efficacy of the Occlutech\u00ae\n      LAA occluder indicated for percutaneous LAA closure in  adult male or female patients with\n      atrial fibrillation. Safety and efficacy will be assessed at day 1, 30 and 90, and after 1\n      year following implantation of an Occlutech\u00ae LAA Occluder."
        }, 
        "brief_title": "Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage (LAA) in Patients With Atrial Fibrillation", 
        "completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Atrial Fibrillation", 
        "condition_browse": {
            "mesh_term": "Atrial Fibrillation"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Documented paroxysmal, persistent or chronic non-valvular AF\n\n          -  Calculated CHA2DS2 -VASC score equal or greater than 2 and/or HAS-BLED score equal or\n             greater than 2\n\n          -  Patients eligible or non-eligible for lifelong, oral anticoagulation therapy\n\n          -  Life expectancy of at least 1 year\n\n          -  Written, informed consent by the patient or her/his legally-authorized representative\n             for participation in the study\n\n        Exclusion Criteria:\n\n          -  Suspected or known intracardiac thrombus\n\n          -  NYHA Class IV CHF\n\n          -  Patients who has unstable and intractable angina pectoris\n\n          -  ASD and/or atrial septal repair or closure device\n\n          -  Recent myocardial infarction within 3 months\n\n          -  Severe valvular heart disease, or implanted mechanical valve prosthesis\n\n          -  Large PFO with significant atrial septal aneurysm\n\n          -  Planned ablation procedure within 30 days of Occlutech LAA occluder\u00ae  implant\n\n          -  Resting heart rate > 110 bpm\n\n          -  Allergy to Nitinol, which is a result of nickel and/or titanium allergies\n\n          -  Stroke/TIA within the last 30 days\n\n          -  Thrombocytopenia, thrombocytosis, leukopenia, or anemia\n\n          -  Symptomatic carotid artery disease\n\n          -  LVEF < 30%\n\n          -  Mitral valve stenosis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "105", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 27, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105584", 
            "org_study_id": "OCC201202", 
            "secondary_id": "CIV-13-09-011614"
        }, 
        "intervention": {
            "arm_group_label": "LAA closure device", 
            "intervention_name": "Implantation of LAA closure device", 
            "intervention_type": "Device", 
            "other_name": "Occlutech LAA occluder in different sizes"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 2, 2014", 
        "location": {
            "contact": {
                "email": "jai-wun.park@klinikum-coburg.de", 
                "last_name": "Jai-Wun Park, Prof"
            }, 
            "facility": {
                "address": {
                    "city": "Coburg", 
                    "country": "Germany", 
                    "zip": "96450"
                }, 
                "name": "Medizinische Klinikum Coburg"
            }, 
            "investigator": [
                {
                    "last_name": "Johannes Brachmann, Prof", 
                    "role": "Principal Investigator"
                }, 
                {
                    "last_name": "Jai-Wun Park, Prof", 
                    "role": "Sub-Investigator"
                }
            ], 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "Prospective, Non-randomized, Safety and Efficacy Study of a New Occluder Design for Minimally Invasive Closure of the Left Atrial Appendage in Patients With Atrial Fibrillation", 
        "overall_contact": {
            "email": "johannes.brachmann.BB@klinikum-Coburg.de", 
            "last_name": "Johannes Brachmann, Prof"
        }, 
        "overall_contact_backup": {
            "last_name": "Jai-Wun Park, Prof"
        }, 
        "overall_official": {
            "affiliation": "Klinikum Coburg", 
            "last_name": "Johannes Brachmann, Prof", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "A major complication is defined as an event that results in death, procedure related stroke, systemic embolism, device embolisation, pericardial effusion (cardiac tamponade), or other major bleeding requiring invasive treatment or blood transfusions.", 
            "measure": "Successful implantation of the Occlutech LAA closure device with less than 7% occurrence of major complications..", 
            "safety_issue": "Yes", 
            "time_frame": "12 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105584"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Occlutech International AB", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Occlutech International AB", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}